Bifunctional bisphosphonates for delivering PTH (1-34) to bone mineral with enhanced bioactivity

Biomaterials

Volumn 34, Issue 12, 2013, Pages 3141-3149

  Yewle, Jivan N ^a   Puleo, David A ^b   Bachas, Leonidas G ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Department of Biology   (United States)

Author keywords

Bioactivity; Bisphosphonate; Bone regeneration; Parathyroid hormone; Protein delivery

Indexed keywords

ALENDRONATE; APOPTOTIC; BIFUNCTIONAL; BINDING AFFINITIES; BINDING ASSAYS; BISPHOSPHONATES; BONE MINERALS; BONE REGENERATION; BONE TISSUE; DRUG DELIVERY VEHICLES; LIPOPHILICITY; MC3T3-E1; N-TERMINALS; PARATHYROID HORMONES; PROTEIN DELIVERY; SINGLE MOLECULE; SKELETAL DISEASE;

ALDEHYDES; BINDING ENERGY; BIOACTIVITY; DISEASES; DRUG DELIVERY; HYDROXYAPATITE; TISSUE;

BONE;

ALDEHYDE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HYDRAZINE BISPHOSPHONIC ACID; HYDROXYAPATITE; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BONE DISEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; LIPOPHILICITY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BONE AND BONES; CELL LINE; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; MICE; MICROSCOPY, FLUORESCENCE; PARATHYROID HORMONE;

EID: 84873464546     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.059     Document Type: Article

References (53)

1. Langer R., Peppas N.A. Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J 2003, 49:2990-3006.
2. Langer R. Drug delivery: drugs on target. Science 2001, 293:58-59.
3. Serda R.E., Godin B., Blanco E., Chiappini C., Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta Gen Subj 2011, 1810:317-329.
4. Cho K., Wang X., Nie S., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
5. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006, 112:630-648.
6. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
7. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41:2971-3010.
8. Hoare T.R., Kohane D.S. Hydrogels in drug delivery: progress and challenges. Polymer 2008, 49:1993-2007.
9. Vermonden T., Censi R., Hennink W.E. Hydrogels for protein delivery. Chem Rev 2012, 112:2853-2888.
10. Zhang S., Gangal G., Uludag H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev 2007, 36:507-531.
11. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002, 8:1929-1944.
12. Wang D., Miller S.C., Shlyakhtenko L.S., Portillo A.M., Liu X.-M., Papangkorn K., et al. Osteotropic peptide that differentiates functional domains of the skeleton. Bioconjug Chem 2007, 18:1375-1378.
13. Wang D., Sima M., Mosley R.L., Davda J.P., Tietze N., Miller S.C., et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm 2006, 3:717-725.
14. Thompson WJ, Thompson DD, Anderson PS, Rodan GA. Polymalonic acids as boneaffinity agents. EP No. 0341961. 1989.
15. Orme M.W., Labroo V.M. Synthesis of [beta]-estradiol-3-benzoate-17-(succinyl-12A-tetracycline): a potential bone-seeking estrogen. Bioorg Med Chem Lett 1994, 4:1375-1380.
16. Zheng H, Weng L. Bone resorption inhibition/osteogenesis promotion pharmaceutical composition. US 5,698,542. 1997.
17. Fischer J., Kolk A., Wolfart S., Pautke C., Warnke P.H., Plank C., et al. Future of local bone regeneration - protein versus gene therapy. J Craniomaxillofac Surg 2011, 39:54-64.
18. Wang G., Mostafa N.Z., Incani V., Kucharski C., Uludag H. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. J Biomed Mater Res Part A 2012, 100A:684-693.
19. Wright J.E.I., Gittens S.A., Bansal G., Kitov P.I., Sindrey D., Kucharski C., et al. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages. Biomaterials 2006, 27:769-784.
20. Uludag H., Kousinioris N., Gao T., Kantoci D. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol Prog 2000, 16:258-267.
21. Gittens S.A., Bagnall K., Matyas J.R., Löbenberg R., Uludag H. Imparting bone mineral affinity to osteogenic proteins through heparin-bisphosphonate conjugates. J Control Release 2004, 98:255-268.
22. Wang G., Babadagli M.E., Uludag H. Bisphosphonate-derivatized liposomes to control drug release from collagen/hydroxyapatite scaffolds. Mol Pharm 2011, 8:1025-1034.
23. Bansal G., Wright J.E.I., Zhang S., Zernicke R.F., Uludag H. Imparting mineral affinity to proteins with thiol-labile disulfide linkages. J Biomed Mater Res Part A 2005, 74A:618-628.
24. Gittens S.A., Matyas J.R., Zernicke R.F., Uludag H. Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates. Pharm Res 2003, 20:978-987.
25. Doschak M.R., Kucharski C.M., Wright J.E.I., Zernicke R.F., Uludag H. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol Pharm 2009, 6:634-640.
26. Zhou H., Lawrence J., Touny A., Bhaduri S. Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V. J Mater Sci Mater Med 2012, 23:365-374.
27. Russell R.G.G. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19.
28. Coleman R.E., McCloskey E.V. Bisphosphonates in oncology. Bone 2011, 49:71-76.
29. Hirabayashi H., Takahashi T., Fujisaki J., Masunaga T., Sato S., Hiroi J., et al. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the osteotropic drug delivery system (ODDS). J Control Release 2001, 70:183-191.
30. Gil L., Han Y., Opas E.E., Rodan G.A., Ruel R., Seedor J.G., et al. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 1999, 7:901-919.
31. Herczegh P., Buxton T.B., McPherson J.C.I., Kovács-Kulyassa á., Brewer P.D., Sztaricskai F., et al. Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials. J Med Chem 2002, 45:2338-2341.
32. Blower P. Towards molecular imaging and treatment of disease with radionuclides: the role of inorganic chemistry. Dalton Trans 2006, 1705-1711.
33. Torres Martin de Rosales R., Finucane C., Foster J., Mather S.J., Blower P.J. 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconjug Chem 2010, 21:811-815.
34. Zaheer A., Lenkinski R.E., Mahmood A., Jones A.G., Cantley L.C., Frangioni J.V. In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol 2001, 19:1148-1154.
35. 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging. Nucl Med Biol 2011, 38:1011-1018.
36. 99mTc-labeled zoledronic acid derivatives. Appl Radiat Isot 2012, 70:848-855.
37. Sibai T., Morgan E., Einhorn T. Anabolic agents and bone quality. Clin Orthop Relat Res 2011, 469:2215-2224.
38. Trivedi R., Goswami R., Chattopadhyay N. Investigational anabolic therapies for osteoporosis. Expert Opin Investig Drugs 2010, 19:995-1005.
39. Henriksen K., Andersen J.R., Riis B.J., Mehta N., Tavakkol R., Alexandersen P., et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis. Bone 2013, 53:160-166.
40. Schetz J.A., Mayr C.A., Taylor J.E., Rosenblatt M., Chorev M., Davis T.P. Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone-related protein in the rat. J Pharmacol Exp Ther 1995, 274:1456-1462.
41. Serada M., Sakurai-Tanikawa A., Igarashi M., Mitsugi K., Takano T., Shibusawa K., et al. The role of the liver and kidneys in the pharmacokinetics of subcutaneously administered teriparatide acetate in rats. Xenobiotica 2012, 42:398-407.
42. Yewle J.N., Puleo D.A., Bachas L.G. Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone. Bioconjug Chem 2011, 22:2496-2506.
43. Liu H., Bargouti M., Zughaier S., Zheng Z., Liu Y., Sangadala S., et al. Osteoinductive LIM mineralization protein-1 suppresses activation of NF-κB and selectively regulates MAPK pathways in pre-osteoclasts. Bone 2010, 46:1328-1335.
44. Mönkkönen H., Rogers M., Makkonen N., Niva S., Auriola S., Mönkkönen J. The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm Res 2001, 18:1550-1555.
45. Kieczykowski G.R., Jobson R.B., Melillo D.G., Reinhold D.F., Grenda V.J., Shinkai I. Preparation of (4-amino-1-hydroxybutylidene)bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids. J Org Chem 1995, 60:8310-8312.
46. Chebbi I., Migianu-Griffoni E., Sainte-Catherine O., Lecouvey M., Seksek O. In vitro assessment of liposomal neridronate on MDA-MB-231 human breast cancer cells. Int J Pharm 2010, 383:116-122.
47. Mikolajczyk S.D., Meyer D.L., Starling J.J., Law K.L., Rose K., Dufour B., et al. High yield, site-specific coupling of N-terminally modified β-lactamase to a proteolytically derived single-sulfhydryl murine Fab'. Bioconjug Chem 1994, 5:636-646.
48. Wolfe C.A.C., Hage D.S. Studies on the rate and control of antibody oxidation by periodate. Anal Biochem 1995, 231:123-130.
49. Geoghegan K.F., Stroh J.G. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. Bioconjug Chem 1992, 3:138-146.
50. Gaertner H.F., Offord R.E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug Chem 1996, 7:38-44.
51. Yewle J.N., Wei Y., Puleo D.A., Daunert S., Bachas L.G. Oriented immobilization of proteins on hydroxyapatite surface using bifunctional bisphosphonates as linkers. Biomacromolecules 2012, 13:1742-1749.
52. Roelofs A.J., Thompson K., Gordon S., Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006, 12:6222s-6230s.
53. Green J., Clézardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol 2010, 37:S3-S11.